ONCASPAR (pegaspargase) is given to patients with acute lymphoblastic leukemia (ALL) as part of a group of chemotherapy medications. ONCASPAR is administered IM/IV* and should not be given more frequently than every 14 days.
For more information, see the Indication and Important Safety Information below, and download the Full Prescribing Information here.
Shire's Resource Helpline
Questions about patient assistance programs, co-pay assistance, and connections to reimbursement specialists should be directed to Shire's Resource Helpline.
US toll-free number: Call 1-888-BAX-8379
Puerto Rico toll-free number: Call 1-844-229-7575
Indication and Usage
ONCASPAR (pegasapragase) is indicated as a component of multi-agent chemotherapeutic regimen for treatment of patients with:
- First-line Acute Lymphoblastic Leukemia (ALL)
- ALL and hypersensitivity to native forms of L-asparaginase.
Detailed Important Safety Information
- History of serious allergic reactions to Oncaspar
- History of serious thrombosis with prior L-asparaginase therapy
- History of pancreatitis with prior L-asparaginase therapy
- History of serious hemorrhagic events with prior L-asparaginase therapy
WARNINGS and PRECAUTIONS
Anaphylaxis and Hypersensitivity: Anaphylaxis or serious allergic reactions can occur; therefore, patients should be observed for one hour after administration. Discontinue ONCASPAR in patients with serious allergic reactions.
Thrombotic Events: Serious thrombotic events, including sagittal sinus thrombosis can occur. Discontinue Oncaspar in patients with serious thrombotic events
Pancreatitis: Pancreatitis can occur. Evaluate patients with abdominal pain for evidence of pancreatitis. Discontinue Oncaspar in patients with pancreatitis
Glucose Intolerance: Glucose intolerance can occur. In some cases, glucose intolerance is irreversible. Monitor serum glucose.
Coagulopathy: Increased prothrombin time, increased partial thromboplastin time, and hypofibrinogenemia can occur. Monitor coagulation parameters at baseline and periodically during and after treatment.
Hepatotoxicity: Hepatotoxicity and abnormal liver function, can occur. Perform appropriate monitoring.
The most common adverse reactions with ONCASPAR (≥2%) are allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, central nervous system (CNS) thrombosis, coagulopathy, hyperbilirubinemia, and elevated transaminases.
Hyperlipidemia (hypercholesterolemia and hypertriglyceridemia) has been reported in patients exposed to ONCASPAR.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088
© 2016 Shire. All rights reserved.
SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates.
ONCASPAR is a registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.
All other product brands or trademarks appearing herein are the property of their respective owners.